Company news

EMV Capital PLC news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Half-year Report

September 30, 2022

PDS Completes $35 Million Financing Agreement

August 25, 2022

Acquisition of 30% Vortex stake & new Vortex CEO

August 16, 2022

PDS Reports Q2 2022 Results & Business Update

August 8, 2022

Holding(s) in Company

June 28, 2022

Result of Placing and Total Voting Rights

June 22, 2022

Proposed Placing to raise at least £1.5 million

June 21, 2022

NetScientific to increase Q-Bot stake to 23.7%

June 17, 2022

Q-Bot secures £1.6m of investment to fund growth

June 15, 2022

PDS Granted FDA Fast Track Designation for PDS0101

June 6, 2022

PDS Biotech - new data for ongoing clinical trials

May 27, 2022

General Counsel Strategic Hire & Grant of Options

May 19, 2022

ProAxsis Update

May 16, 2022

Final Results

May 12, 2022

PDS Reports Q1 2022 Results & Business Update

May 11, 2022

Notice of Results & Investor Presentation

May 9, 2022

Acquisition of 30% of Vortex Biotech Holdings

May 6, 2022

PDS Provides Business Update & Full-Year Results

March 31, 2022

Publication of Shareholder Newsletter

March 4, 2022

PDS Announces Preliminary Safety Data on PDS0101

February 24, 2022

PDS Clinical Trial with Mayo Clinic

February 15, 2022

PDS Phase 2 Trial Update

February 2, 2022

PDS Announces Preclinical Data for PDS0202 Vaccine

January 28, 2022

PDS Granted Novel HPV16 Immunotherapy Patent

January 10, 2022

ProAxsis CEO End of Year Update

January 10, 2022

Issue of Equity

December 29, 2021

TR-1: Form for notification of major holdings

December 21, 2021

Q-Bot Investment and Share Acquisition

December 21, 2021

Acquisition of majority stake in Cetromed

December 20, 2021

Martlet Capital Update

December 13, 2021

PDS Phase 2 Clinical Trial Update

December 6, 2021

$1million investment in portfolio company, EpiBone

November 26, 2021

PDS Reports Q3 2021 Results & Business Update

November 10, 2021

Sofant Signs EUR7.3m ESA Contract

November 4, 2021

PDS to License Novel Proteins for Flu Vaccine

November 1, 2021

EMV Capital Participates in £843k Sofant Funding

October 26, 2021

ProAxsis announces the approval of a key US patent

October 22, 2021

Investor Presentations

October 4, 2021

Grant of Options to Directors

September 29, 2021

Notice of Results and Analyst Briefing

September 20, 2021

Investment in Martlet Capital Limited

September 16, 2021

Result of General Meeting, TVR & PDMR Dealings

June 28, 2021

PDS Announces Closing of c. $52m Public Offering

June 22, 2021

NSCI Participates in $45m PDS Equity Issue

June 16, 2021

PDS announces proposed offering of common stock

June 15, 2021

Proposed Placing

June 10, 2021

PDS Announces Release of PDS0101 Interim Data

June 8, 2021

PDS Announces Release of PDS0101 Abstract

May 20, 2021

PDS receives $4.5m from net sale of tax benefits

May 18, 2021

PDS Reports Results for Q1 2021 & Business Update

May 13, 2021

← Newer news releases · Older news releases →

Calls

The 5 newest of 14 calls. Every call is listed under its year.

Decks

The 5 newest of 15 decks. Every deck is listed under its year.